QCLS - MyMD Pharmaceuticals, Inc.

4.5
1.020   22.667%

Share volume: 10,881,422
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$3.48
1.02
0.29%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 35%
Dept financing 42%
Liquidity 11%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
20.00%
1 Month
5.88%
3 Months
-34.78%
6 Months
19.36%
1 Year
1,116.22%
2 Year
147.25%
Key data
Stock price
$4.50
P/E Ratio 
0.00
DAY RANGE
$3.41 - $4.97
EPS 
-$7.58
52 WEEK RANGE
$0.04 - $8.94
52 WEEK CHANGE
$1,163.69
MARKET CAP 
6.156 M
YIELD 
N/A
SHARES OUTSTANDING 
4.167 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.66
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,632,872
AVERAGE 30 VOLUME 
$830,546
Company detail
CEO: Mitchell Glass
Region: US
Website: tnfpharma.com
Employees: 6
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Recent news